Medical research

Cancer drug lessens the toxicity of a protein from COVID-19 virus

University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2—the virus that causes COVID-19—and then used an FDA-approved cancer drug to blunt the viral protein's ...

Immunology

Will COVID-19 vaccines need to be adapted regularly?

Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses. Will the same apply to COVID-19 vaccines? In order to gauge whether and to what extent this may be necessary, ...

Medical research

Untangling COVID-19 and tuberculosis

As the UK marks one year since the country went into lockdown, we've also been looking further afield to countries disproportionately burdened by infectious diseases, including COVID-19. To mark this year's World TB Day, ...

Medications

New drug candidate against COVID-19

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, arrived one year ago and turned our lives upside-down.

Diseases, Conditions, Syndromes

SARS-CoV-2 viral-specific antibody response profiles vary with age

(HealthDay)—Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral-specific antibody response profiles are distinct in different age groups, according to a study published online March 22 in JAMA Network Open.

page 7 from 40